Citadel Advisors
HELX icon

Citadel Advisors’s Franklin Genomic Advancements ETF HELX Stock Holding History

Citadel Advisors’s Portfolio HELX Stock Details HELX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.35M Sell
33,800
-3,768
-10% -$131K ﹤0.01% 7461
2026
Q1 		$1.24M Buy
+37,568
New +$1.31M ﹤0.01% 7185
2025
Q3 		– Sell
-63,368
Closed -$1.76M – 13320
2025
Q2 		$1.76M Buy
63,368
+17,249
+37% +$457K ﹤0.01% 5951
2025
Q1 		$1.25M Buy
46,119
+38,153
+479% +$1.12M ﹤0.01% 6478
2024
Q4 		$230K Buy
+7,966
New +$244K ﹤0.01% 10193
2024
Q2 		– Sell
-11,072
Closed -$363K – 14741
2024
Q1 		$363K Buy
+11,072
New +$346K ﹤0.01% 9061

Other funds holding HELX

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Citadel Advisors's HELX Position: Q2 2026 in Review

Citadel Advisors reduced its Franklin Genomic Advancements ETF (HELX) stake by 10% in Q2 2026, selling an estimated $131K and leaving 33,800 shares worth $1.35M. The position accounts for ﹤0.01% of the portfolio, ranked #7461.

Citadel Advisors first reported a position in HELX in Q1 2024 and has held it in 6 quarters since. The position peaked at $1.76M in Q2 2025. 6 funds tracked by Wall St. Rank hold HELX as of Q2 2026.

  • Citadel Advisors held 33,800 shares of Franklin Genomic Advancements ETF worth $1.35M as of Q2 2026.
  • Citadel Advisors sold 3,768 Franklin Genomic Advancements ETF shares in Q2 2026, an estimated $131K.
  • Franklin Genomic Advancements ETF made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #7461 holding.
  • Citadel Advisors first reported a position in Franklin Genomic Advancements ETF in Q1 2024 and has held it in 6 quarters since.
  • Citadel Advisors's Franklin Genomic Advancements ETF position peaked at $1.76M in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Franklin Genomic Advancements ETF as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.